Eur Rev Med Pharmacol Sci 2022; 26 (13): 4872-4880

DOI: 10.26355/eurrev_202207_29212

N-acetylcysteine as a therapeutic approach to post-COVID-19 pulmonary fibrosis adjunctive treatment

C. Micheletto, J.L. Izquierdo, S.N. Avdeev, R.A. Rada Escobar, M.C. Pacheco Gallego

Respiratory Unit, Cardio-Thoracic Department, Integrated University Hospital of Verona, Verona, Italy. mcpachecog@utp.edu.co


OBJECTIVE: Growing interest is directed to the outcomes of COVID-19 in survivors, both in the convalescent period and in the long-term, which are responsible for morbidity and quality of life deterioration. This article aims to describe the mechanisms supporting the possible use of NAC as an adjuvant treatment for post-COVID-19 pulmonary fibrosis.

MATERIALS AND METHODS: A search was performed in PubMed/MEDLINE.

RESULTS: Interstitial changes have been observed in the CT scan of COVID-19 pneumonia. In patients with respiratory outcomes in the post-COVID-19 stage, glutathione (GSH) deficiency was found and interpreted as a reaction to the inflammatory cascade caused by the viral infection, while the pathophysiological process of pulmonary fibrosis involves numerous cytokines, such as TGF-β, TNF-α, IL-1, PDGF and VEGF. NAC has a good tolerability profile, is easily administered orally and inexpensively, and has antioxidant and anti-inflammatory effects that may target the pathophysiologic mechanisms involved in pulmonary fibrosis. It may revert GSH deficiency, exerts direct and indirect antioxidant activity, anti-inflammatory activity and improves immune T-cell response.

CONCLUSIONS: The mechanism of action of NAC suggests a role in the treatment of pulmonary fibrosis induced by COVID-19.

Free PDF Download

To cite this article

C. Micheletto, J.L. Izquierdo, S.N. Avdeev, R.A. Rada Escobar, M.C. Pacheco Gallego
N-acetylcysteine as a therapeutic approach to post-COVID-19 pulmonary fibrosis adjunctive treatment

Eur Rev Med Pharmacol Sci
Year: 2022
Vol. 26 - N. 13
Pages: 4872-4880
DOI: 10.26355/eurrev_202207_29212